Department of Anesthesiology and Critical Care Medicine, CHU de Québec-Université Laval, Québec, Quebec, Canada
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
BMJ Open. 2023 Mar 1;13(3):e070748. doi: 10.1136/bmjopen-2022-070748.
For close to a century opioid administration has been a standard of care to complement anaesthesia during surgery. Considering the worldwide opioid epidemic, this practice is now being challenged and there is a growing use of systemic pharmacological opioid minimising strategies. Our aim is to conduct a scoping review that will examine clinical trials that have evaluated the impact of intraoperative opioid minimisation strategies on patient-centred outcomes and identify promising strategies.
Our scoping review will follow the framework developed by Arksey and O'Malley. We will search MEDLINE, Embase, CENTRAL, Web of Science and CINAHL from their inception approximately in March 2023. We will include randomised controlled trials, assessing the impact of systemic intraoperative pharmacologic opioid minimisation strategies on patient-centred outcomes. We define an opioid minimisation strategy as any non-opioid drug with antinociceptive properties administered during the intraoperative period. Patient-centred outcomes will be defined and classified based on the consensus definitions established by the Standardised Endpoints in Perioperative Medicine initiative (StEP-COMPAC group) and informed by knowledge users and patient partners. We will use a coproduction approach involving interested parties. Our multidisciplinary team includes knowledge users, patient partners, methodologists and knowledge user organisations. Knowledge users will provide input on methods, outcomes, clinical significance of findings, implementation and feasibility. Patient partners will participate in assessing the relevance of our design, methods and outcomes and help to facilitate evidence translation. We will provide a thorough description of available clinical trials, compare their reported patient-centred outcome measures with established recommendations and identify promising strategies.
Ethics approval is not required for the review. Our scoping review will inform future research including clinical trials and systematic reviews through identification of important intraoperative interventions. Results will be disseminated through a peer-reviewed publication, presentation at conferences and through our network of knowledge user collaborators.
Open Science Foundation (currently embargoed).
近一个世纪以来,阿片类药物的应用一直是手术期间辅助麻醉的标准治疗方法。考虑到全球阿片类药物流行,这种做法现在正受到挑战,并且越来越多地使用系统药理学阿片类药物最小化策略。我们的目的是进行一项范围界定审查,该审查将检查评估术中阿片类药物最小化策略对以患者为中心的结果影响的临床试验,并确定有前途的策略。
我们的范围界定审查将遵循 Arksey 和 O'Malley 制定的框架。我们将从大约 2023 年 3 月开始在 MEDLINE、Embase、CENTRAL、Web of Science 和 CINAHL 中进行搜索。我们将纳入评估系统术中药理学阿片类药物最小化策略对以患者为中心的结果影响的随机对照试验。我们将阿片类药物最小化策略定义为在手术期间给予的具有镇痛作用的任何非阿片类药物。以围手术期医学标准化终点倡议(StEP-COMPAC 小组)确定的共识定义为基础并通过知识使用者和患者伙伴提供信息,将定义和分类以患者为中心的结果。我们将采用涉及相关方的共同生产方法。我们的多学科团队包括知识使用者、患者伙伴、方法学家和知识用户组织。知识使用者将提供有关方法、结果、发现的临床意义、实施和可行性的投入。患者伙伴将参与评估我们的设计、方法和结果的相关性,并帮助促进证据转化。我们将提供对现有临床试验的详细描述,将其报告的以患者为中心的结果测量指标与既定建议进行比较,并确定有前途的策略。
审查不需要伦理批准。我们的范围界定审查将通过确定重要的术中干预措施,为未来的研究提供信息,包括临床试验和系统评价。结果将通过同行评议的出版物、会议演示和我们的知识用户合作者网络进行传播。
开放科学基金会(目前被搁置)。